

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM346511

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Silicon Valley Bank		10/31/2014	CORPORATION: CALIFORNIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Sagent Pharmaceuticals, Inc.		
<b>Street Address:</b>	1901 North Roselle Road		
<b>Internal Address:</b>	Suite 700		
<b>City:</b>	Schaumburg		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60195		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4063563	ADVANCE INJECTABLES EXCELLENCE	
<b>Registration Number:</b>	4063564	CREATE INJECTABLES EXCELLENCE	
<b>Registration Number:</b>	4063565	DISCOVER INJECTABLES EXCELLENCE	
<b>Registration Number:</b>	4063566	INVEST IN INJECTABLES EXCELLENCE	
<b>Registration Number:</b>	3743423	SAGENT PHARMACEUTICALS	
<b>Registration Number:</b>	3729987	SSS	
<b>Registration Number:</b>	4088164	SSS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3128622200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	3128622000		
<b>Email:</b>	rob.soneson@kirkland.com		
<b>Correspondent Name:</b>	Rob Soneson		
<b>Address Line 1:</b>	300 N LaSalle		
<b>Address Line 2:</b>	Kirkland & Ellis LLP		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60654		
<b>ATTORNEY DOCKET NUMBER:</b>	11417-1-RFS		
<b>NAME OF SUBMITTER:</b>	Rob Soneson		

CH \$190.00 4063563

<b>SIGNATURE:</b>	/rsoneson/
<b>DATE SIGNED:</b>	07/01/2015
<b>Total Attachments: 6</b> source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page1.tif source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page2.tif source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page3.tif source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page4.tif source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page5.tif source=10-31-2014 - Trademark Release - Silicon Valley-Sagent#page6.tif	

**RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT**

**THIS RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this “Release”) is made as of October 31, 2014 (“Effective Date”) by SILICON VALLEY BANK, a California corporation, with its principal office at 3003 Tasman Drive, Santa Clara, California 95054 (“Grantee”), in favor of SAGENT PHARMACEUTICALS, INC., a Delaware corporation, with its principal office at 1901 North Roselle Road, Suite 700, Schaumburg, Illinois 60195 (“Grantor”).

**WHEREAS**, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement by and between Grantor and Grantee dated February 13, 2012 (the “Intellectual Property Security Agreement”), Grantor granted to Grantee a security interest in and to all of Grantor’s right, title and interest in, to and under the Intellectual Property Collateral (as defined in the Intellectual Property Security Agreement), including, without limitation, the United States copyrights set forth on Exhibit A attached hereto, the United States patents set forth on Exhibit B attached hereto, the United States trademarks set forth on Exhibit C attached hereto, and the United States mask works set forth on Exhibit D;

**WHEREAS**, Grantor and Grantee entered into the Intellectual Property Security Agreement pursuant to the terms and conditions of that certain Loan and Security Agreement by and among Grantor, Grantee and Sagent Pharmaceuticals, a Wyoming corporation, dated February 13, 2012 (the “Loan Agreement”);

**WHEREAS**, the Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office (“PTO”) on February 14, 2012, at Reel 4717, Frame 0234 and at Reel 027700, Frame 0437, and with the United States Copyright Office on February 16, 2012 at Document V3613D470;

**WHEREAS**, Grantor has paid all of its outstanding indebtedness to Grantee.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

Grantee hereby terminates the Intellectual Property Security Agreement, and hereby terminates, cancels and releases any and all security interests it has against the Intellectual Property Collateral.


Grantee represents and warrants that: (i) it has the full power and authority to execute this Release; (ii) it has not assigned, transferred, restricted or otherwise encumbered any security interest it has against the intellectual property; and (iii) it has not recorded or otherwise evidenced its security interest with respect to any intellectual property owned by Grantor, other than that set forth on Exhibits A, B and C (attached hereto), in any jurisdiction throughout the world.

Grantee shall take all further actions, and provide to Grantor, Grantor’s successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), requested by Grantor to more fully and effectively effectuate the purposes of this Release.

\* \* \* \* \*

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

Silicon Valley Bank

 \_\_\_\_\_

Name: Jesse Mayer

Title: VP

**EXHIBIT A**

**Copyrights**

<b>Description</b>	<b>Registration/Application Number</b>	<b>Registration/Application Date</b>
Heparin_20,000 USP units per mL - 1 mL_package insert_40401	VA0001720701	5/11/2010

**EXHIBIT B**

**U.S. PATENTS**

<b>Description</b>	<b>Registration/Application Number</b>	<b>Registration/Application Date</b>
Product Viewer	App. 12/505230 (Pub. 20100017747)	7/17/2009
Label, labeling system and method of labeling for containers for drug products	App. 13/175175 (Pub. 20120000592)	7/1/2011

**EXHIBIT C**  
**TRADEMARKS**

<b>Description</b>	<b>Registration/ Application Number</b>	<b>Registration/ Application Date</b>
ADVANCE INJECTABLES EXCELLENCE	4063563	11/29/2011
CREATE INJECTABLES EXCELLENCE	4063564	11/29/2011
DISCOVER INJECTABLES EXCELLENCE	4063565	11/29/2011
INVEST IN INJECTABLES EXCELLENCE	4063566	11/29/2011
SAGENT PHARMACEUTICALS	3743423	1/26/2010
SSS & Design	3729987	12/22/2009
SSS & Design	4088164	1/17/2012

**EXHIBIT D**  
**MASK WORKS**

**None.**